A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-11-11

AUTHORS

Sandra P. D’Angelo, Omid A. Hamid, Ahmad Tarhini, Dirk Schadendorf, Bartosz Chmielowski, Frances A. Collichio, Anna C. Pavlick, Karl D. Lewis, Susan C. Weil, John Heyburn, Charles Schweizer, Daniel J. O’Shannessy, Richard D. Carvajal

ABSTRACT

Objectives Ontuxizumab (MORAB-004) is a first-in-class monoclonal antibody that interferes with endosialin function, which is important in tumor stromal cell function, angiogenesis, and tumor growth. This Phase 2 study evaluated the 24-week progression-free survival (PFS) value, pharmacokinetics, and tolerability of 2 doses of ontuxizumab in patients with metastatic melanoma. Patients and methods Patients with metastatic melanoma and disease progression after receiving at least 1 prior systemic treatment were randomized to receive ontuxizumab (2 or 4 mg/kg) weekly, without dose change, until disease progression. Results Seventy-six patients received at least 1 dose of ontuxizumab (40 received 2 mg/kg, 36 received 4 mg/kg). The primary endpoint, 24-week PFS value, was 11.4% (95% Confidence Interval [CI]: 5.3%–19.9%) for all patients (13.5% for 2 mg/kg and 8.9% for 4 mg/kg). The median PFS for all patients was 8.3 weeks (95% CI: 8.1–12.3 weeks). One patient receiving 4 mg/kg had a partial response, as measured by Response Evaluation Criteria in Solid Tumors v1.1. Twenty-seven of 66 response evaluable patients (40.9%) had stable disease. The median overall survival was 31.0 weeks (95% CI: 28.3–44.0 weeks). The most common adverse events overall were headache (55.3%), fatigue (48.7%), chills (42.1%), and nausea (36.8%), mostly grade 1 or 2. Conclusions Ontuxizumab at both doses was well tolerated. The 24-week PFS value was 11.4% among all ontuxizumab-treated patients. The overall response rate was 3.1% at the 4 mg/kg dose, with clinical benefit achieved in 42.4% of response evaluable patients. Efficacy of single-agent ontuxizumab at these doses in melanoma was low. More... »

PAGES

103-113

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-017-0530-4

DOI

http://dx.doi.org/10.1007/s10637-017-0530-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1092633476

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29127533


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, CD", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Weill Cornell Medical College, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "Memorial Sloan Kettering Cancer Center, New York, NY, USA", 
            "Weill Cornell Medical College, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "D\u2019Angelo", 
        "givenName": "Sandra P.", 
        "id": "sg:person.01122566752.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122566752.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Angeles Clinic and Research Institute, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.488730.0", 
          "name": [
            "The Angeles Clinic and Research Institute, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hamid", 
        "givenName": "Omid A.", 
        "id": "sg:person.0575703507.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0575703507.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pittsburgh, Pittsburgh, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.21925.3d", 
          "name": [
            "University of Pittsburgh, Pittsburgh, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tarhini", 
        "givenName": "Ahmad", 
        "id": "sg:person.0743573635.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743573635.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e4tsklinikum Essen, Essen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.410718.b", 
          "name": [
            "Universit\u00e4tsklinikum Essen, Essen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schadendorf", 
        "givenName": "Dirk", 
        "id": "sg:person.01117256754.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117256754.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "University of California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chmielowski", 
        "givenName": "Bartosz", 
        "id": "sg:person.01270326576.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270326576.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of North Carolina, Chapel Hill, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.410711.2", 
          "name": [
            "University of North Carolina, Chapel Hill, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Collichio", 
        "givenName": "Frances A.", 
        "id": "sg:person.011104144247.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011104144247.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "New York University, Lake Success, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.137628.9", 
          "name": [
            "New York University, Lake Success, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pavlick", 
        "givenName": "Anna C.", 
        "id": "sg:person.01276612250.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276612250.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Colorado Cancer Center, Aurora, CO, USA", 
          "id": "http://www.grid.ac/institutes/grid.499234.1", 
          "name": [
            "University of Colorado Cancer Center, Aurora, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lewis", 
        "givenName": "Karl D.", 
        "id": "sg:person.0740154633.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740154633.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Morphotek, Inc., Exton, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418767.b", 
          "name": [
            "Morphotek, Inc., Exton, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Weil", 
        "givenName": "Susan C.", 
        "id": "sg:person.0643502505.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643502505.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Morphotek, Inc., Exton, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418767.b", 
          "name": [
            "Morphotek, Inc., Exton, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heyburn", 
        "givenName": "John", 
        "id": "sg:person.016342070457.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016342070457.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Morphotek, Inc., Exton, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418767.b", 
          "name": [
            "Morphotek, Inc., Exton, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schweizer", 
        "givenName": "Charles", 
        "id": "sg:person.0615612166.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615612166.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Morphotek, Inc., Exton, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418767.b", 
          "name": [
            "Morphotek, Inc., Exton, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "O\u2019Shannessy", 
        "givenName": "Daniel J.", 
        "id": "sg:person.01052134007.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052134007.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Columbia University Medical Center, 177 Ft Washington Avenue, 10032, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.239585.0", 
          "name": [
            "Columbia University Medical Center, 177 Ft Washington Avenue, 10032, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carvajal", 
        "givenName": "Richard D.", 
        "id": "sg:person.0726366600.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40257-014-0083-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051468955", 
          "https://doi.org/10.1007/s40257-014-0083-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12307-015-0168-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045899429", 
          "https://doi.org/10.1007/s12307-015-0168-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10456-006-9061-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020865888", 
          "https://doi.org/10.1007/s10456-006-9061-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-11-11", 
    "datePublishedReg": "2017-11-11", 
    "description": "Objectives Ontuxizumab (MORAB-004) is a first-in-class monoclonal antibody that interferes with endosialin function, which is important in tumor stromal cell function, angiogenesis, and tumor growth. This Phase 2 study evaluated the 24-week progression-free survival (PFS) value, pharmacokinetics, and tolerability of 2 doses of ontuxizumab in patients with metastatic melanoma. Patients and methods Patients with metastatic melanoma and disease progression after receiving at least 1 prior systemic treatment were randomized to receive ontuxizumab (2 or 4\u00a0mg/kg) weekly, without dose change, until disease progression. Results Seventy-six patients received at least 1 dose of ontuxizumab (40 received 2\u00a0mg/kg, 36 received 4\u00a0mg/kg). The primary endpoint, 24-week PFS value, was 11.4% (95% Confidence Interval [CI]: 5.3%\u201319.9%) for all patients (13.5% for 2\u00a0mg/kg and 8.9% for 4\u00a0mg/kg). The median PFS for all patients was 8.3\u00a0weeks (95% CI: 8.1\u201312.3\u00a0weeks). One patient receiving 4\u00a0mg/kg had a partial response, as measured by Response Evaluation Criteria in Solid Tumors v1.1. Twenty-seven of 66 response evaluable patients (40.9%) had stable disease. The median overall survival was 31.0\u00a0weeks (95% CI: 28.3\u201344.0\u00a0weeks). The most common adverse events overall were headache (55.3%), fatigue (48.7%), chills (42.1%), and nausea (36.8%), mostly grade 1 or 2. Conclusions Ontuxizumab at both doses was well tolerated. The 24-week PFS value was 11.4% among all ontuxizumab-treated patients. The overall response rate was 3.1% at the 4\u00a0mg/kg dose, with clinical benefit achieved in 42.4% of response evaluable patients. Efficacy of single-agent ontuxizumab at these doses in melanoma was low.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10637-017-0530-4", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438793", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "keywords": [
      "response-evaluable patients", 
      "phase 2 study", 
      "metastatic melanoma", 
      "evaluable patients", 
      "disease progression", 
      "PFS values", 
      "progression-free survival values", 
      "monoclonal antibodies", 
      "prior systemic treatment", 
      "Solid Tumors v1.1", 
      "median overall survival", 
      "common adverse events", 
      "Response Evaluation Criteria", 
      "overall response rate", 
      "stromal cell function", 
      "class monoclonal antibody", 
      "median PFS", 
      "stable disease", 
      "primary endpoint", 
      "Methods Patients", 
      "partial response", 
      "overall survival", 
      "systemic treatment", 
      "adverse events", 
      "clinical benefit", 
      "ontuxizumab", 
      "Results Seventy", 
      "dose changes", 
      "patients", 
      "response rate", 
      "tumor growth", 
      "grade 1", 
      "melanoma", 
      "cell function", 
      "doses", 
      "dose", 
      "progression", 
      "weeks", 
      "antibodies", 
      "tolerability", 
      "nausea", 
      "headache", 
      "pharmacokinetics", 
      "PFS", 
      "endosialin", 
      "disease", 
      "endpoint", 
      "weekly", 
      "angiogenesis", 
      "survival value", 
      "efficacy", 
      "survival", 
      "treatment", 
      "chills", 
      "study", 
      "v1.1", 
      "evaluation criteria", 
      "fatigue", 
      "response", 
      "function", 
      "criteria", 
      "benefits", 
      "rate", 
      "events", 
      "changes", 
      "values", 
      "seventies", 
      "growth"
    ], 
    "name": "A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma", 
    "pagination": "103-113", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1092633476"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-017-0530-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29127533"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-017-0530-4", 
      "https://app.dimensions.ai/details/publication/pub.1092633476"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_745.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10637-017-0530-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-017-0530-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-017-0530-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-017-0530-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-017-0530-4'


 

This table displays all metadata directly associated to this object as RDF triples.

311 TRIPLES      21 PREDICATES      110 URIs      99 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-017-0530-4 schema:about N02ef8fdbf38f4afc8d6fe8e5c01b858b
2 N26539a6f22a840cf8ef4c971195fae12
3 N43eb4d1250ee407f94dfdf26ce02f122
4 N5818944f0ae84de686dd9623634b89a1
5 N79032052c9f34430b0f64a85b40da11d
6 N8c1b8cd017ac4384a7ce2ab18f797de1
7 N8f7a5f2ace0e43229045eb06fc3c52dc
8 N9181615f07404192a461132212c0dd46
9 N963020b8ca054795850b02596863925b
10 Na3c077b276764818a66e294c82a9bb60
11 Nb9ec6b5a400540b48b9e73d817c1a1dc
12 Nd35b782e51ea43f8b5415faa108ecf1f
13 Nddfefad38a2c4a23b251bf3e50f2f6ef
14 Ne99a17868b44423b848f30ffd996b9e0
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author N429292eeea6240f5adf1e624e9d70534
18 schema:citation sg:pub.10.1007/s10456-006-9061-x
19 sg:pub.10.1007/s12307-015-0168-8
20 sg:pub.10.1007/s40257-014-0083-7
21 schema:datePublished 2017-11-11
22 schema:datePublishedReg 2017-11-11
23 schema:description Objectives Ontuxizumab (MORAB-004) is a first-in-class monoclonal antibody that interferes with endosialin function, which is important in tumor stromal cell function, angiogenesis, and tumor growth. This Phase 2 study evaluated the 24-week progression-free survival (PFS) value, pharmacokinetics, and tolerability of 2 doses of ontuxizumab in patients with metastatic melanoma. Patients and methods Patients with metastatic melanoma and disease progression after receiving at least 1 prior systemic treatment were randomized to receive ontuxizumab (2 or 4 mg/kg) weekly, without dose change, until disease progression. Results Seventy-six patients received at least 1 dose of ontuxizumab (40 received 2 mg/kg, 36 received 4 mg/kg). The primary endpoint, 24-week PFS value, was 11.4% (95% Confidence Interval [CI]: 5.3%–19.9%) for all patients (13.5% for 2 mg/kg and 8.9% for 4 mg/kg). The median PFS for all patients was 8.3 weeks (95% CI: 8.1–12.3 weeks). One patient receiving 4 mg/kg had a partial response, as measured by Response Evaluation Criteria in Solid Tumors v1.1. Twenty-seven of 66 response evaluable patients (40.9%) had stable disease. The median overall survival was 31.0 weeks (95% CI: 28.3–44.0 weeks). The most common adverse events overall were headache (55.3%), fatigue (48.7%), chills (42.1%), and nausea (36.8%), mostly grade 1 or 2. Conclusions Ontuxizumab at both doses was well tolerated. The 24-week PFS value was 11.4% among all ontuxizumab-treated patients. The overall response rate was 3.1% at the 4 mg/kg dose, with clinical benefit achieved in 42.4% of response evaluable patients. Efficacy of single-agent ontuxizumab at these doses in melanoma was low.
24 schema:genre article
25 schema:isAccessibleForFree true
26 schema:isPartOf N8a97e4a8a56c4fcf9ce1f3ffbf7e9366
27 Ne63cc5ab68204e388d3bf55e6b3c3af6
28 sg:journal.1094201
29 schema:keywords Methods Patients
30 PFS
31 PFS values
32 Response Evaluation Criteria
33 Results Seventy
34 Solid Tumors v1.1
35 adverse events
36 angiogenesis
37 antibodies
38 benefits
39 cell function
40 changes
41 chills
42 class monoclonal antibody
43 clinical benefit
44 common adverse events
45 criteria
46 disease
47 disease progression
48 dose
49 dose changes
50 doses
51 efficacy
52 endosialin
53 endpoint
54 evaluable patients
55 evaluation criteria
56 events
57 fatigue
58 function
59 grade 1
60 growth
61 headache
62 median PFS
63 median overall survival
64 melanoma
65 metastatic melanoma
66 monoclonal antibodies
67 nausea
68 ontuxizumab
69 overall response rate
70 overall survival
71 partial response
72 patients
73 pharmacokinetics
74 phase 2 study
75 primary endpoint
76 prior systemic treatment
77 progression
78 progression-free survival values
79 rate
80 response
81 response rate
82 response-evaluable patients
83 seventies
84 stable disease
85 stromal cell function
86 study
87 survival
88 survival value
89 systemic treatment
90 tolerability
91 treatment
92 tumor growth
93 v1.1
94 values
95 weekly
96 weeks
97 schema:name A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma
98 schema:pagination 103-113
99 schema:productId N016db4d8bf7d445599c4cd6f60951683
100 N51fc7116b036416db1c6f64192485afc
101 N89a215f0b2924d5cae3a930795cf83cc
102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092633476
103 https://doi.org/10.1007/s10637-017-0530-4
104 schema:sdDatePublished 2022-12-01T06:36
105 schema:sdLicense https://scigraph.springernature.com/explorer/license/
106 schema:sdPublisher N83c7ad5f031f4df09f09fe0486ec7b91
107 schema:url https://doi.org/10.1007/s10637-017-0530-4
108 sgo:license sg:explorer/license/
109 sgo:sdDataset articles
110 rdf:type schema:ScholarlyArticle
111 N016db4d8bf7d445599c4cd6f60951683 schema:name doi
112 schema:value 10.1007/s10637-017-0530-4
113 rdf:type schema:PropertyValue
114 N02ef8fdbf38f4afc8d6fe8e5c01b858b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Melanoma
116 rdf:type schema:DefinedTerm
117 N0c24fdb1b4c74fb7bc6d48fe7c30b1fd rdf:first sg:person.0615612166.04
118 rdf:rest Nafabb45af2f246eb9f458f27972c782c
119 N13df618b332d4529ba6cc8d879ea8ae7 rdf:first sg:person.0740154633.51
120 rdf:rest Nf3ad26ef15f341eeba67b39c34c77c9f
121 N26539a6f22a840cf8ef4c971195fae12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Antibodies, Monoclonal, Humanized
123 rdf:type schema:DefinedTerm
124 N429292eeea6240f5adf1e624e9d70534 rdf:first sg:person.01122566752.19
125 rdf:rest N4580c80776ad48aab3bb08d59480b9e1
126 N43eb4d1250ee407f94dfdf26ce02f122 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Middle Aged
128 rdf:type schema:DefinedTerm
129 N4580c80776ad48aab3bb08d59480b9e1 rdf:first sg:person.0575703507.41
130 rdf:rest Nb68c0da006c34a2587b91c5f6f57e7fb
131 N491927447e7c46138f940e04dd69c052 rdf:first sg:person.016342070457.73
132 rdf:rest N0c24fdb1b4c74fb7bc6d48fe7c30b1fd
133 N51fc7116b036416db1c6f64192485afc schema:name dimensions_id
134 schema:value pub.1092633476
135 rdf:type schema:PropertyValue
136 N5818944f0ae84de686dd9623634b89a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Aged, 80 and over
138 rdf:type schema:DefinedTerm
139 N5a129a40855242fc9ac352a7d4beb988 rdf:first sg:person.01270326576.37
140 rdf:rest Nc6821f1b96fb46eeb1338411facaa580
141 N71e76a2fc3a344bbb8bcfce47adeaa80 rdf:first sg:person.01276612250.59
142 rdf:rest N13df618b332d4529ba6cc8d879ea8ae7
143 N79032052c9f34430b0f64a85b40da11d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Male
145 rdf:type schema:DefinedTerm
146 N83c7ad5f031f4df09f09fe0486ec7b91 schema:name Springer Nature - SN SciGraph project
147 rdf:type schema:Organization
148 N89a215f0b2924d5cae3a930795cf83cc schema:name pubmed_id
149 schema:value 29127533
150 rdf:type schema:PropertyValue
151 N8a97e4a8a56c4fcf9ce1f3ffbf7e9366 schema:volumeNumber 36
152 rdf:type schema:PublicationVolume
153 N8c1b8cd017ac4384a7ce2ab18f797de1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Treatment Outcome
155 rdf:type schema:DefinedTerm
156 N8f7a5f2ace0e43229045eb06fc3c52dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Aged
158 rdf:type schema:DefinedTerm
159 N9181615f07404192a461132212c0dd46 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Antineoplastic Agents
161 rdf:type schema:DefinedTerm
162 N9584d996835f40069a2f25bf6092b0b0 rdf:first sg:person.0726366600.25
163 rdf:rest rdf:nil
164 N963020b8ca054795850b02596863925b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Female
166 rdf:type schema:DefinedTerm
167 Na3c077b276764818a66e294c82a9bb60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Antigens, Neoplasm
169 rdf:type schema:DefinedTerm
170 Nafabb45af2f246eb9f458f27972c782c rdf:first sg:person.01052134007.71
171 rdf:rest N9584d996835f40069a2f25bf6092b0b0
172 Nb68c0da006c34a2587b91c5f6f57e7fb rdf:first sg:person.0743573635.60
173 rdf:rest Nf9fc86662dd5408d8862ea78af34144f
174 Nb9ec6b5a400540b48b9e73d817c1a1dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Kaplan-Meier Estimate
176 rdf:type schema:DefinedTerm
177 Nc6821f1b96fb46eeb1338411facaa580 rdf:first sg:person.011104144247.43
178 rdf:rest N71e76a2fc3a344bbb8bcfce47adeaa80
179 Nd35b782e51ea43f8b5415faa108ecf1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Adult
181 rdf:type schema:DefinedTerm
182 Nddfefad38a2c4a23b251bf3e50f2f6ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Humans
184 rdf:type schema:DefinedTerm
185 Ne63cc5ab68204e388d3bf55e6b3c3af6 schema:issueNumber 1
186 rdf:type schema:PublicationIssue
187 Ne99a17868b44423b848f30ffd996b9e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Antigens, CD
189 rdf:type schema:DefinedTerm
190 Nf3ad26ef15f341eeba67b39c34c77c9f rdf:first sg:person.0643502505.57
191 rdf:rest N491927447e7c46138f940e04dd69c052
192 Nf9fc86662dd5408d8862ea78af34144f rdf:first sg:person.01117256754.05
193 rdf:rest N5a129a40855242fc9ac352a7d4beb988
194 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
195 schema:name Medical and Health Sciences
196 rdf:type schema:DefinedTerm
197 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
198 schema:name Oncology and Carcinogenesis
199 rdf:type schema:DefinedTerm
200 sg:grant.2438793 http://pending.schema.org/fundedItem sg:pub.10.1007/s10637-017-0530-4
201 rdf:type schema:MonetaryGrant
202 sg:journal.1094201 schema:issn 0167-6997
203 1573-0646
204 schema:name Investigational New Drugs
205 schema:publisher Springer Nature
206 rdf:type schema:Periodical
207 sg:person.01052134007.71 schema:affiliation grid-institutes:grid.418767.b
208 schema:familyName O’Shannessy
209 schema:givenName Daniel J.
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052134007.71
211 rdf:type schema:Person
212 sg:person.011104144247.43 schema:affiliation grid-institutes:grid.410711.2
213 schema:familyName Collichio
214 schema:givenName Frances A.
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011104144247.43
216 rdf:type schema:Person
217 sg:person.01117256754.05 schema:affiliation grid-institutes:grid.410718.b
218 schema:familyName Schadendorf
219 schema:givenName Dirk
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117256754.05
221 rdf:type schema:Person
222 sg:person.01122566752.19 schema:affiliation grid-institutes:grid.5386.8
223 schema:familyName D’Angelo
224 schema:givenName Sandra P.
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122566752.19
226 rdf:type schema:Person
227 sg:person.01270326576.37 schema:affiliation grid-institutes:grid.19006.3e
228 schema:familyName Chmielowski
229 schema:givenName Bartosz
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270326576.37
231 rdf:type schema:Person
232 sg:person.01276612250.59 schema:affiliation grid-institutes:grid.137628.9
233 schema:familyName Pavlick
234 schema:givenName Anna C.
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276612250.59
236 rdf:type schema:Person
237 sg:person.016342070457.73 schema:affiliation grid-institutes:grid.418767.b
238 schema:familyName Heyburn
239 schema:givenName John
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016342070457.73
241 rdf:type schema:Person
242 sg:person.0575703507.41 schema:affiliation grid-institutes:grid.488730.0
243 schema:familyName Hamid
244 schema:givenName Omid A.
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0575703507.41
246 rdf:type schema:Person
247 sg:person.0615612166.04 schema:affiliation grid-institutes:grid.418767.b
248 schema:familyName Schweizer
249 schema:givenName Charles
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615612166.04
251 rdf:type schema:Person
252 sg:person.0643502505.57 schema:affiliation grid-institutes:grid.418767.b
253 schema:familyName Weil
254 schema:givenName Susan C.
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643502505.57
256 rdf:type schema:Person
257 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.239585.0
258 schema:familyName Carvajal
259 schema:givenName Richard D.
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
261 rdf:type schema:Person
262 sg:person.0740154633.51 schema:affiliation grid-institutes:grid.499234.1
263 schema:familyName Lewis
264 schema:givenName Karl D.
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740154633.51
266 rdf:type schema:Person
267 sg:person.0743573635.60 schema:affiliation grid-institutes:grid.21925.3d
268 schema:familyName Tarhini
269 schema:givenName Ahmad
270 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743573635.60
271 rdf:type schema:Person
272 sg:pub.10.1007/s10456-006-9061-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1020865888
273 https://doi.org/10.1007/s10456-006-9061-x
274 rdf:type schema:CreativeWork
275 sg:pub.10.1007/s12307-015-0168-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045899429
276 https://doi.org/10.1007/s12307-015-0168-8
277 rdf:type schema:CreativeWork
278 sg:pub.10.1007/s40257-014-0083-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051468955
279 https://doi.org/10.1007/s40257-014-0083-7
280 rdf:type schema:CreativeWork
281 grid-institutes:grid.137628.9 schema:alternateName New York University, Lake Success, NY, USA
282 schema:name New York University, Lake Success, NY, USA
283 rdf:type schema:Organization
284 grid-institutes:grid.19006.3e schema:alternateName University of California, Los Angeles, CA, USA
285 schema:name University of California, Los Angeles, CA, USA
286 rdf:type schema:Organization
287 grid-institutes:grid.21925.3d schema:alternateName University of Pittsburgh, Pittsburgh, PA, USA
288 schema:name University of Pittsburgh, Pittsburgh, PA, USA
289 rdf:type schema:Organization
290 grid-institutes:grid.239585.0 schema:alternateName Columbia University Medical Center, 177 Ft Washington Avenue, 10032, New York, NY, USA
291 schema:name Columbia University Medical Center, 177 Ft Washington Avenue, 10032, New York, NY, USA
292 rdf:type schema:Organization
293 grid-institutes:grid.410711.2 schema:alternateName University of North Carolina, Chapel Hill, NC, USA
294 schema:name University of North Carolina, Chapel Hill, NC, USA
295 rdf:type schema:Organization
296 grid-institutes:grid.410718.b schema:alternateName Universitätsklinikum Essen, Essen, Germany
297 schema:name Universitätsklinikum Essen, Essen, Germany
298 rdf:type schema:Organization
299 grid-institutes:grid.418767.b schema:alternateName Morphotek, Inc., Exton, PA, USA
300 schema:name Morphotek, Inc., Exton, PA, USA
301 rdf:type schema:Organization
302 grid-institutes:grid.488730.0 schema:alternateName The Angeles Clinic and Research Institute, Los Angeles, CA, USA
303 schema:name The Angeles Clinic and Research Institute, Los Angeles, CA, USA
304 rdf:type schema:Organization
305 grid-institutes:grid.499234.1 schema:alternateName University of Colorado Cancer Center, Aurora, CO, USA
306 schema:name University of Colorado Cancer Center, Aurora, CO, USA
307 rdf:type schema:Organization
308 grid-institutes:grid.5386.8 schema:alternateName Weill Cornell Medical College, New York, NY, USA
309 schema:name Memorial Sloan Kettering Cancer Center, New York, NY, USA
310 Weill Cornell Medical College, New York, NY, USA
311 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...